For forty years, children and young adults diagnosed with osteosarcoma have faced a disease that medicine has largely been unable to outpace — survival rates remain poor, and metastatic cases offer little hope. Now, researchers at St. Jude Children's Research Hospital have identified a two-drug combination that, in laboratory models, disrupts the cancer's machinery in ways neither drug could achieve alone. The discovery is not yet a treatment, but in a field long starved of new directions, it marks something rare: a rationally grounded reason for cautious hope.
Dual-drug approach targets aggressive osteosarcoma in preclinical study
Osteosarcoma is a pediatric bone cancer with poor survival rates, particularly in metastatic cases, affecting children and young adults.
A disease that hasn't had a major therapeutic improvement for a long time
Mark
So this is a combination of two drugs that work together against osteosarcoma. What makes that different from just using one drug?
Mimi
The key is that they work synergistically—each one makes the other more effective. One drug degrades a protein called EP300 that cancer cells use to turn on cancer genes. The other blocks AKT, which is a central control switch in cells. Together, they slow tumor growth more than either alone.
Luke
But this is all in mouse models with human tumor samples grafted in, right? Not actual patients yet?
Mimi
That's correct. It's preclinical. The real test will come when this moves into human trials.
Mark
Why hasn't osteosarcoma had a new treatment in 40 years? Is it just a rare disease?
Mimi
It's rare enough that there's less commercial incentive, but it's also genuinely difficult to treat. Survival rates are lower than many other cancers, and when it spreads, outcomes are especially poor. That combination of factors has meant less research attention.
Luke
The paper identifies AKT mutations as a potential biomarker for sensitivity. How confident are we that this will hold up? Is it just the tumors they tested?
Mimi
They found that most of the osteosarcoma samples that responded to EP300 degradation had AKT pathway mutations. That's a meaningful pattern, but you're right to be cautious—it's based on their sample set. Real predictive power will only come from larger studies.
Mark
What about the protein production rate finding? That seems like it could matter for other cancers too.
Mimi
Exactly. They discovered that resistant tumors make proteins faster, which lets them outpace the degradation. That's a general principle that could apply to any protein degrader therapy. It's a way to predict which patients might fail treatment.
Luke
But we don't have a clinical test for protein production rates yet, do we?
Mimi
Not that I'm aware of. That's another bridge to cross before this becomes a practical tool in the clinic.
El Pulso
- Osteosarcoma has resisted every attempt at therapeutic innovation for four decades, leaving patients with metastatic disease in a near-hopeless position.
- St. Jude researchers found that pairing an EP300 degrader with an AKT inhibitor produced a synergistic effect in mouse models carrying actual patient tumor samples — each drug amplifying the other's impact.
- The key tension lies in tumor biology itself: resistant cancers simply manufacture proteins faster than the drugs can destroy them, threatening to undermine not just this therapy but the entire emerging class of protein degraders.
- Scientists turned this vulnerability into a diagnostic tool, identifying that tumors with AKT pathway mutations respond most strongly — potentially making those mutations a biomarker for treatment eligibility.
- The work remains preclinical, but its genotype-to-therapy logic mirrors strategies already succeeding in leukemia, charting a credible path toward human trials.
For forty years, children and young adults diagnosed with osteosarcoma have faced a disease that medicine has largely been unable to outpace — survival rates remain poor, and metastatic cases offer little hope. Now, researchers at St. Jude Children's Research Hospital have identified a two-drug combination that, in laboratory models, disrupts the cancer's machinery in ways neither drug could achieve alone. The discovery is not yet a treatment, but in a field long starved of new directions, it marks something rare: a rationally grounded reason for cautious hope.
Osteosarcoma, a bone cancer striking children and young adults, has defeated therapeutic progress for forty years. Survival rates are poor, and when the disease spreads, outcomes grow grimmer still. That long stasis is what gives new findings from St. Jude Children's Research Hospital their weight: researchers have identified a two-drug combination that slowed tumor growth and extended survival in laboratory models.
The strategy targets two distinct weaknesses simultaneously. One drug degrades EP300, a protein cancer cells exploit to activate disease-driving genes. The other inhibits AKT, a cellular regulator already targeted by FDA-approved drugs in other cancers. Together in mouse models carrying patient tumor samples, the pair produced effects neither could achieve alone. Co-corresponding author Adam Durbin called the approach especially promising for patients with metastatic disease — those with the fewest remaining options.
The discovery came from asking why only some tumors responded to EP300 degradation. The answer was written in the tumor's DNA: responsive cancers tended to carry mutations that hyperactivated the AKT pathway. That observation made the combination therapy a logical next step — and it worked.
The research also revealed something with broader implications. Sensitive tumors produced proteins more slowly overall, while resistant ones outpaced the drugs by manufacturing proteins faster than they could be broken down. This suggests that cancer cells may be able to overwhelm protein degraders — a growing class of therapies — simply by accelerating their own production machinery. But it also means that slower protein synthesis could predict which patients will respond.
Computational biologist Brian Abraham framed the approach as a genotype-to-therapy strategy, echoing methods already transforming leukemia care. The work has not yet entered human trials, but for a disease that has resisted innovation for a generation, it offers a concrete and rationally grounded new direction.
Osteosarcoma, a bone cancer that strikes children and young adults, has been a stubborn clinical problem. Survival rates lag behind many other cancers, and when the disease spreads or returns, outcomes grow grimmer still. For four decades, no fundamentally new treatment has reached patients. That stasis is what makes a finding published this week in the Journal of Experimental Medicine worth attention: researchers at St. Jude Children's Research Hospital have identified a two-drug combination that slowed tumor growth and extended survival in laboratory models of the disease.
The approach targets two distinct vulnerabilities. One drug degrades EP300, a protein that cancer cells hijack to activate cancer-driving genes. The other inhibits AKT, a cellular regulator that goes haywire in many malignancies and already has FDA-approved inhibitors on the market. When deployed together in mouse models carrying patient tumor samples, the pair produced a synergistic effect—each drug amplified what the other could do.
The discovery emerged from a methodical hunt through tumor genetics. Researchers noticed that only a subset of osteosarcoma samples responded strongly to EP300 degradation. They asked why. The answer lay in the tumor's DNA: most of the responsive tumors carried mutations that hyperactivated the AKT pathway. That observation pointed toward a rational strategy: combine the EP300 degrader with an AKT inhibitor. The pairing worked. Adam Durbin, co-corresponding author and an oncologist at St. Jude, described it as especially promising for patients with metastatic disease—those least helped by existing therapies.
Underlying the synergy is a principle about how cells manage their own machinery. When researchers compared sensitive tumors to resistant ones, they found a crucial difference: the sensitive cancers produced proteins at a slower rate overall. Resistant tumors, by contrast, seemed to outpace the degradation process by manufacturing proteins faster than the drugs could break them down. This insight has implications far beyond osteosarcoma. Pharmaceutical companies are developing protein degraders for many diseases. If cancer cells can simply ramp up protein production to overwhelm the therapy, that mechanism could undermine treatment in other contexts. But the St. Jude team has shown that this same vulnerability can be turned into an advantage—by identifying which tumors have slower protein synthesis, clinicians might predict which patients will respond.
The findings suggest that AKT mutations could serve as a biomarker, a genetic flag that signals which patients might benefit from the combination. Brian Abraham, a computational biologist and co-corresponding author, framed it as a genotype-to-therapy strategy, an approach that has already proven valuable in leukemia treatment. The work remains preclinical—it has not yet moved into human trials. But for a disease that has resisted therapeutic innovation for decades, it represents a concrete new direction to pursue, particularly for the patients whose tumors have already spread and who have run out of conventional options.
Citas Notables
We found a compound combination that looks promising for a disease that is exceptionally challenging to treat and has not had a major therapeutic improvement for a long time, especially exciting because the approach may have potential in patients who are metastatic and are least responsive to current therapies.— Adam Durbin, M.D., Ph.D., St. Jude Department of Oncology
One way to make a degrader less effective is to make more proteins than the cell can degrade. Resistant osteosarcomas seem to be able to 'outrun' EP300 degradation by making more proteins overall.— Brian Abraham, Ph.D., St. Jude Department of Computational Biology
Quieres la nota completa?
Lee el original en Medical Xpress ↗
Health & Medicine